# Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

> **NCT07314216** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 15 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Carcinoma)
- Stage III
- EGFR Uncommon Mutations

## Interventions

- **DRUG:** Firmonertinib
- **RADIATION:** Definitive Thoracic Radiotherapy

## Key facts

- **NCT ID:** NCT07314216
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07314216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07314216, "Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07314216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*